Hypoglycemia is a condition in which a person’s glucose, or blood sugar, level is lower than normal. It most often, although not exclusively, occurs in patients with drug-treated type 1 (T1D) or type 2 diabetes mellitus (T2D), as glucose-lowering medications can lead to hypoglycemia (Silbert et al., 2018). Symptoms of hypoglycemia include fatigue, fast heartbeat, shakiness, anxiety, and hunger. During a severe hypoglycemic episode, symptoms can escalate to blurred vision, confusion, seizures, or even loss of consciousness. In those without diabetes, causes of hypoglycemia can include excessive alcohol intake, taking certain medications, and hormone deficiencies (Mayo Clinic, 2021).
The publisher epidemiologists utilized nationally representative and country-specific peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of hypoglycemia. For the 7MM, hypoglycemia cases attributed to T1D, T2D, and all diabetes were segmented by age, sex, and severity. Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes in incidence throughout the forecast period.
The publisher epidemiologists forecast that the diagnosed incident cases of hypoglycemia attributed to T1D and T2D in the 7MM will grow by an annual growth rate (AGR) of 0.21% over the next 10 years, from 1,483,850 cases in 2020 to 1,515,114 cases in 2030. Diagnosed incident cases of non-diabetic hypoglycemia will increase from 479,409 cases in 2020 to 489,344 cases in 2030 in the 7MM, at an AGR of 0.21%. These trends mirror changes in the underlying, at-risk populations, such as the rising incidence of T2D, the most common type of diabetes. While hypoglycemia has long been recognized as an inevitable consequence of diabetes therapy, it is being increasingly viewed as a potentially preventable cause of impaired quality of life and mortality.
The publisher epidemiologists utilized nationally representative and country-specific peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed incident cases of hypoglycemia. For the 7MM, hypoglycemia cases attributed to T1D, T2D, and all diabetes were segmented by age, sex, and severity. Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes in incidence throughout the forecast period.
The publisher epidemiologists forecast that the diagnosed incident cases of hypoglycemia attributed to T1D and T2D in the 7MM will grow by an annual growth rate (AGR) of 0.21% over the next 10 years, from 1,483,850 cases in 2020 to 1,515,114 cases in 2030. Diagnosed incident cases of non-diabetic hypoglycemia will increase from 479,409 cases in 2020 to 489,344 cases in 2030 in the 7MM, at an AGR of 0.21%. These trends mirror changes in the underlying, at-risk populations, such as the rising incidence of T2D, the most common type of diabetes. While hypoglycemia has long been recognized as an inevitable consequence of diabetes therapy, it is being increasingly viewed as a potentially preventable cause of impaired quality of life and mortality.
Scope
- The Hypoglycemia Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Hypoglycemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of hypoglycemia attributed to type 1 and type 2 diabetes. The diagnosed incident cases are segmented by age (0-9 years, and by 10-year age groups for age 10 years up to 80 years and older) and sex. The diagnosed incident cases of hypoglycemia attributed to all diabetes are additionally segmented by severity (non-severe versus severe) and, among severe cases, by hospitalized incident cases. The diagnosed incident cases of hypoglycemia in the non-diabetic and bariatric surgery populations are also forecasted.
- The hypoglycemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy
The Hypoglycemia Epidemiology series will allow you to -- Develop business strategies by understanding the trends shaping and driving the global hypoglycemia markets.
- Quantify patient populations in the global hypoglycemia markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hypoglycemia therapeutics in each of the markets covered.
- Understand magnitude of the hypoglycemia population by age, sex, and severity.
Table of Contents
1 Hypoglycemia: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
